After three virtual editions, we are extremely pleased to announce that the 8th NovAliX Conference Biophysics in Drug Discovery is back and scheduled on May 9-11, 2022 in the fantastic city of Munich, Germany. In addition, we are excited to let you know that to provide access to a broader audience, virtual participation will also be possible!
The live event offering unprecedented social experiences will be specifically designed to enhance the meshing and mingling opportunities with peer scientists along the conference. The professionally broadcasted conference will allow distant participants to enjoy a high-quality digital experience.
This eighth edition of the NovAliX Conference aims to bring together the community of biophysicists, structural biologists, pharmacologists and medicinal chemists, to explore synergies between their disciplines to deliver better drugs on a shorter timeline.
Indeed many pharmaceutical companies have set up in-house biophysical and structural biology platforms to speed up the target-to-candidate process and improve the quality of small-molecule therapeutics through a better understanding of their interactions with their targets. Academic labs involved in early-stage drug discovery also heavily rely on biophysical and structural biology techniques. And many synchrotron facilities now also include cryo-EM to offer a more complete, versatile panel of structure determination capacities, in particular for drug discovery projects.
The preliminary Scientific Programme includes the following sessions:
- Biophysical approaches for RNAs as therapeutics and therapeutic targets
- Emerging techniques for the measurement of in-cell interactions
- Use of biophysical tools and structural biology to understand the molecular mechanism of induced-proximity agents (PROTACs, molecular glues, etc...)
- Biophysics in covalent drug discovery
- Hot Topics
The programme will also include moderated roundtable discussions on hot topics to spur debate with the on-site audience. Selected exhibitors will be presenting their latest drug discovery enabling products. In addition, to further promote scientific interactions for the participants, there will be both an active on-site and virtual poster session.
The full scientific event will be accessible to all registered delegates, both on site in Munich and via top notch broadcasting to be enjoyed from remote.
Further details on the hybrid format and benefits for both types of participation will be announced soon, but in any case, don’t miss the opportunity to join us for this next-level kind of conference!
Jean-Paul Renaud
NovAliX Conferences Chairman
